Trials / Completed
CompletedNCT02976753
Prospective, Non-interventional Study to Evaluate the Effectiveness of Elocta Compared to Conventional Factor Products
24-month Prospective, Multicentre, Non-interventional Study to Evaluate the Effectiveness of Elocta Compared to Conventional Factor Products in the Prophylactic Treatment of Patients With Haemophilia A (A-SURE)
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 361 (actual)
- Sponsor
- Swedish Orphan Biovitrum · Industry
- Sex
- Male
- Age
- —
- Healthy volunteers
- Not accepted
Summary
The purpose of the study is to evaluate the effectiveness of Elocta compared to conventional factor products in the prophylactic treatment of patients with haemophilia A over a 24-month prospective period. Data will also be collected for a 12 month retrospective period.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | efmoroctocog alfa | extended half-life factor VIII product |
| DRUG | Factor VIII | conventional factor VIII product |
Timeline
- Start date
- 2016-12-01
- Primary completion
- 2021-11-03
- Completion
- 2021-11-03
- First posted
- 2016-11-29
- Last updated
- 2024-10-02
Locations
36 sites across 9 countries: Austria, Belgium, Finland, France, Italy, Norway, Spain, Sweden, United Kingdom
Source: ClinicalTrials.gov record NCT02976753. Inclusion in this directory is not an endorsement.